Recent trends in lipid management: Raising the bar and shifting the goalposts?

Internal Medicine Journal

Volumn 33, Issue 3, 2003, Pages 95-102

  Sullivan, David R ^a  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

Cardiovascular disease; Lipids; Prevention

Indexed keywords

CHOLESTEROL ESTER TRANSFER PROTEIN; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PHOSPHOLIPID; STATIN;

BODY WEIGHT; CARDIOVASCULAR DISEASE; CEREAL; CLINICAL PRACTICE; DEGENERATIVE DISEASE; DIET; DYSLIPIDEMIA; EXERCISE; FAMILIAL HYPERCHOLESTEROLEMIA; FAMILY HISTORY; FUTUROLOGY; HUMAN; HYPERTRIGLYCERIDEMIA; ISCHEMIC HEART DISEASE; LIPID ANALYSIS; LIPID BLOOD LEVEL; LIPIDOSIS; MOLECULAR MECHANICS; MULTIFACTORIAL INHERITANCE; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PUBLIC HEALTH; REVIEW; RISK FACTOR; SMOKING CESSATION; TRIACYLGLYCEROL BLOOD LEVEL;

HUMANS; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA, FAMILIAL COMBINED; HYPERLIPIDEMIAS; HYPERLIPOPROTEINEMIA TYPE II; HYPERTRIGLYCERIDEMIA; PROGNOSIS;

EID: 0037346715     PISSN: 14440903     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1445-5994.2003.00364.x     Document Type: Review

References (34)

1. Heart Protection Study Collaborative Group. Medical Research Council/British Heart Foundation heart protection study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
2. Simons LA, Simons J, McManus P, Dudley J. Discontinuation rates for use of statins are high. Br Med J 2000; 321: 1084.
3. Gotto AM Jr, Grundy SM. Lowering LDL cholesterol: questions from recent meta-analyses and subset analyses of clinical trial. Data Issues from the Interdisciplinary Council on Reducing the Risk for Coronary Heart Disease, ninth Council meeting. Circulation 1999; 99: E1-7.
4. Bellosta S, Paoletti R. Statin therapy and prevention of stroke. Current Atherosclerosis Reports 2000; 2: 181-82.
5. Chan KA, Andrade SE, Boles M, Buist DSM, Chase GA, Donahue JG et al. Inhibitors of hydroxymethylglutaryl-coenzyme A: reductase and risk of fracture among older women. Lancet 2000; 355: 2185-88.
6. Ray JG, Mamdani M, Tsuyuki RT, Anderson DR, Yeo EL, Laupacis A. Use of statins and the subsequent development of deep vein thrombosis. Arch Intern Med 2001; 161: 1405-10.
7. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. Lancet 2000; 356: 1627-31.
8. Hall NF, Gale CR, Syddall H, Phillips DI, Martyn CN. Risk of macular degeneration in users of statins: cross sectional study. Br Med J 2001; 323: 375-76.
9. Rust S, Rosier M, Funke H, Real J, Amoura Z, Piette JC et al. Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nature Genet 1999; 22: 352-5.
10. Clee SM, Kastelein JJ, van Dam M, Marcil M, Roomp K, Zwarts KY et al. Age and residual cholesterol efflux affect HDL cholesterol levels and coronary artery disease in ABCA1 heterozygotes. J Clin Invest 2000; 106: 1263-70.
11. Berge KE, Tian H, Graf GA, Yu L, Grishin NV, Schultz J et al. Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters. Science 2000; 290: 1771-75.
12. Wilson J. The Barker hypothesis. An analysis. Aust NZ J Obstet Gynaecol 1999; 39: 1-7.
13. National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand. Lipid Management Guidelines 2001. Med J Aust 2001; 175: S57-88.
14. Hoy W, Kelly A, Jacups S, McKendry K, Baker P, MacDonald S et al. Stemming the tide: reducing cardiovascular disease and renal failure in Australian Aborigines. Aust NZ J Med 1999; 29: 480-83.
15. Jackson R. Updated New Zealand cardiovascular disease risk-benefit prediction guide. Br Med J 2000; 320: 709-10.
16. Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet 2000; 356: 1423-30.
17. Distler O, Cooper DA, Deckelbaum RJ, Sturley SL. Hyperlipidemia and inhibitors of HIV protease. Curr Opin Clin Nutr Metab Care 2001; 4: 99-103.
18. Silberberg J, Fryer J, Wlodarczyk J, Robertson R, Dear K. Comparison of family history measures used to identify high risk of coronary heart disease. Genetic Epidemiol 1999; 16 (Suppl): 344-55.
19. Bhatnagar D, Morgan J, Siddiq S, Mackness MI, Miller JP, Durrington PN. Outcome of case finding among relatives of patients with known heterozygous familial hypercholesterolaemia. Br Med J 2000; 321: 1497-500.
20. Bunn CF, Lintott CJ, Scott RS, George PM. Comparison of SSCP and DHPLC for the detection of LDLR mutations in a New Zealand cohort. Human Mutation 2002; 19: 311.
21. Umans-Eckenhausen MA, Defesche JC, Sijbrands EJ, Scheerder RL, Kastelein JJ. Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands. Lancet 2001; 357: 165-8.
22. Goldman L, Goldman PA, Williams LW, Weinstein MC. Cost-effectiveness considerations in the treatment of heterozygous familial hypercholesterolemia with medications. Am J Cardiol 1993; 72: 75-79D.
23. Veerkamp MJ, de Graaf J, Bredie SJ, Hendricks JC, Demacker PN, Stalenhof AF. Diagnosis of familial combined hyperlipidaemia based on lipid phenotype expression in 32 families: results of a 5-year follow-up study. Arterioscler Thromb Vasc Biol 2002; 22: 274-82.
24. McNeely MJ, Edwards KL, Marcovina SM, Brunzell JD, Motulsky AG, Austin MA. Lipoprotein and apolipoprotein abnormalities in familial combined hyperlipidaemia: a 20-year prospective study. Atheroscler 2001; 159: 471-81.
25. Schnyder G, Roffi M, Pin R, Flammer Y, Lange H, Eberli FR et al. Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Eng J Med 2001; 345: 1593-600.
26. Rifai N, Ridker PM. High-sensitivity C-reactive protein: a novel and promising marker of coronary heart disease. Clin Chem 2001; 47: 403-11.
27. Leaf A, Kang JX, Xiao YF, Billman GE, Voskuyl RA. The antiarrhythmic and anticonvulsant effects of dietary N-3 fatty acids. J Membrane Biol 1999; 172: 1-11.
28. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D et al. Effects of atorvastatin on early recurrent ischaemic events in acute coronary syndromes. JAMA 2001; 285: 1711-8.
29. Contacos C, Barter PJ, Sullivan DR. Effect of pravastatin and omega-3 fatty acids on plasma lipids and lipoproteins in patients with combined hyperlipidemia. Arterioscler Thromb 1993; 13: 1755-62.
30. Guijarro C, Blanco-Colio LM, Ortego M, Alonso C, Ortiz A, Plaza JJ et al. 3-Hydroxy-3-methylglutaryl coenzyme a reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture. Circ Res 1998; 83: 490-500.
31. Jialal I, Stein D, Balis D, Grundy SM, Adams-Huet B, Devaraj S. Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 2001; 103: 1933-5.
32. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999; 341: 410-8.
33. Chinetti G, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm Res 2000; 49: 497-505.
34. Expert Panel on the Detection Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NECP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.